WallStreetZenWallStreetZen

NASDAQ: PCRX
Pacira Biosciences Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Pacira Biosciences revenue was $705.85M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q2 2025) ending on Jun 30, 2025 was $181.1M, up 7.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, PCRX annual revenue was $701.0M, with 3.9% growth year-over-year.

PCRX past revenue growth

How has PCRX's revenue growth performed historically?

Company
2.25%
Industry
6.85%
Market
20.34%
PCRX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
PCRX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
PCRX's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

PCRX revenue history

Current Revenue
$705.8M
Current Earnings
-$127.5M
Current Profit Margin
-18.1%

Be the first to know when PCRX announces revenue.

PCRX Revenue History By Year

PCRX Yearly RevenuePCRX RevenuePCRX ChangePCRX Revenue Growth
2024-12-31$700.97M$25.99M+3.85%
2023-12-31$674.98M$8.16M+1.22%
2022-12-31$666.82M$125.29M+23.14%
2021-12-31$541.53M$111.89M+26.04%
2020-12-31$429.65M$8.62M+2.05%
2019-12-31$421.03M$83.75M+24.83%
2018-12-31$337.28M$50.65M+17.67%
2017-12-31$286.63M$10.26M+3.71%
2016-12-31$276.37M$27.37M+10.99%
2015-12-31$249.00M$51.33M+25.97%
2014-12-31$197.67M$112.12M+131.05%
2013-12-31$85.55M$46.47M+118.89%
2012-12-31$39.08M$23.40M+149.12%
2011-12-31$15.69M$1.13M+7.74%
2010-12-31$14.56M-$444.00k-2.96%
2009-12-31$15.01M$1.08M+7.76%
2008-12-31$13.93M$5.58M+66.95%
2007-12-31$8.34MN/AN/A

1 of 2

Pacira Biosciences Revenue FAQ

What was PCRX's revenue last quarter?

On Invalid Date, Pacira Biosciences (NASDAQ: PCRX) reported Q2 2025 revenue of $181.10 million up 1.73% year over year. In the same quarter last year, Pacira Biosciences's revenue was $178.02 million.

What was Pacira Biosciences's revenue in 2024?

Pacira Biosciences's annual revenue for the twelve months ending Dec 31, 2024 was $700.97 million, a 3.85% increase year over year.

How much does Pacira Biosciences make in a day?

Based on Pacira Biosciences annual revenue for the past five years, PCRX makes an average of $1,651,477.81 per day.

What was Pacira Biosciences's annual revenue growth in the past year?

As of Q4 2025, Pacira Biosciences's revenue has grown 2.25% year over year. This is 4.6 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 6.85%. Pacira Biosciences's revenue in the past year totaled $705.85 million.

How much does Pacira Biosciences make in a year?

Pacira Biosciences's revenue by year for the past five years is:
  • Pacira Biosciences's revenue for the twelve months ending Dec 31, 2024 was $700.97 million, a 3.85% increase year over year.
  • Pacira Biosciences's annual revenue for Dec 31, 2023 was $674.98 million, a 1.22% increase from 2022.
  • Pacira Biosciences's annual revenue for 2022 was $666.82 million, a 23.14% increase from 2021.
  • Pacira Biosciences's annual revenue for 2021 was $541.53 million, a 26.04% increase from 2020.
  • Pacira Biosciences's annual revenue for 2020 was $429.65 million, a 2.05% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.